Seeking Alpha

Dutch Trader

View as an RSS Feed
View Dutch Trader's Comments BY TICKER:
Latest  |  Highest rated
  • BG Medicine - Just Be Patient [View article]
    BG Medicine, Inc. Announces Proposed Public Offering of Common Stock

    WALTHAM, Mass., April 2, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. BG Medicine also expects to grant the underwriters a 30-day option to purchase additional shares of common stock to cover over-allotments, if any. Lazard Capital Markets LLC is acting as sole book-running manager for the offering. While the offering is expected to price before 9:30 am EDT on April 3, 2014, the offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

    A registration statement on Form S-3 relating to the common stock offered in this offering was filed with, and declared effective by, the Securities and Exchange Commission (the "SEC"). A preliminary prospectus supplement, as well as a final prospectus supplement, relating to and describing the terms of the offering will be filed with the SEC, each of which will form a part of the effective registration statement. When available, copies of the preliminary and final prospectus supplements relating to these securities may be obtained by visiting the SEC's website at or from Lazard Capital Markets LLC, 30 Rockefeller Plaza, 60th Floor, New York, NY 10020 or via telephone at (212) 632-6717.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
    Apr 2 04:28 PM | Likes Like |Link to Comment
  • SGOCO Group - A Turnaround Story With All Eyes On Q4 Results [View article]
    Okay, I am in! Despite I didn't do any due diligence. Who is the auditor?
    Apr 2 02:23 PM | Likes Like |Link to Comment
  • Kingold Jewelry CEO Discusses Q4 2013 Results - Earnings Call Transcript [View article]
    What would happen if the related party loan would have been defaulted?

    I am sorry, I have been long this stock but sold today with a loss. These kind of actions are out of control and show a lack of weak corporate governance.
    Apr 1 01:29 PM | 2 Likes Like |Link to Comment
  • Kingold Jewelry, A Stock To Watch In The Year Of The Horse [View article]
    The related party loan was a red flag, that again shows the risk of the VIE-structure.
    Apr 1 01:22 PM | Likes Like |Link to Comment
  • American Lorain, An Undervalued Opportunity [View article]
    Yes, we need some explanation! The main question: Which plans does management have to grow their business?
    Apr 1 04:36 AM | Likes Like |Link to Comment
  • Avoid King's IPO And Buy Glu Mobile [View article]
    I agree with you. KING's IPO disaster is overdone and I really think a price around $18 is a fair entry point for a very profitable company.
    Mar 29 02:52 PM | Likes Like |Link to Comment
  • Willi-Food International Should Be Taken Private For A Potential 100% Gain [View article]
    Besides the undervaluation of the company, I think Mr. Granovsky wants to expand in the food sector and is this one of his first buyouts. I guess we will hear from him more this year. Maybe his goal is to make the biggest kosher food company in the world.
    Mar 24 01:26 PM | Likes Like |Link to Comment
  • G. Willi Food-International, Ltd. News Creates A Buying Opportunity [View article]
    I bought some shares for our fund RJT Capital today.

    Have a look at this:

    And tell me which opportunities this represent!
    Mar 20 06:04 PM | Likes Like |Link to Comment
  • Arch Therapeutics And The Advanced Wound Closure Market [View article]
    They believe that they could submit it as medical device, at least in Europe. But if not then they will need additional financing.
    Mar 13 07:38 AM | Likes Like |Link to Comment
  • Arch Therapeutics And The Advanced Wound Closure Market [View article]
    A very promising company, but now we have to wait until the next catalyst will hit the screen. This is one of those life science companies that belong in a long term portfolio. Dilution will be part of the story, but if they can bring their product to the market in a relatively short time period the stock price will increase accordingly.

    Personally I think we will see a much higher stock price for Arch this year.
    Mar 10 03:59 PM | Likes Like |Link to Comment
  • American Lorain, An Undervalued Opportunity [View article]
    I don't know how it works specifically for Morgan Stanley, but from experience I know that only some micro cap funds are allowed to allocate to investments with market caps below 200m, in most cases there are more restrictions such as stock price, average volume, etc.

    If MS runs small cap funds, private equity funds or closed end funds in the US then it could be that they were allowed this type of investment. Which seems so, otherwise they weren't invested in the first place.

    The investment policies (read: restrictions) of asset managers changes almost every year. It depends on management decisions, economic outlook and more factors.
    Feb 18 11:19 AM | Likes Like |Link to Comment
  • American Lorain, An Undervalued Opportunity [View article]
    You are right. The decrease could have something to do with their investment policy. No stocks below $5 and a minimum market cap of $200m.

    Despite that we saw some heavy volume after December 31, so their place could be replaced by institutional investors who have the ability to allocate holdings in micro caps.
    Feb 18 09:17 AM | Likes Like |Link to Comment
  • A Deeper Look At The Galena Biopharma Controversy [View article]
    There is value left in Galena because it's considered an acquisition target. For now, I would recommend "never catch a falling knife". I think when the stock price is bottomed out, investors that are familiar with the risks can jump on the bandwagon again.
    Feb 14 09:50 AM | 4 Likes Like |Link to Comment
  • American Lorain, An Undervalued Opportunity [View article]
    Also a new 13G filing
    Feb 13 05:48 PM | Likes Like |Link to Comment
  • American Lorain, An Undervalued Opportunity [View article]
    American Lorain announces acquisition of controlling interest in Europe based chestnut manufacturer and distributor (ALN) : Co announced that it has acquired 51% share capital in Athena Group ("Athena"), a France based prepared foods manufacturer and distributor with a diversified product portfolio including chestnuts, bean sprouts, as well as a variety of other Asian imported food products, for an aggregate cash consideration of €1,995,000, or approximately US$2,702,650.
    The website of the target company:
    Feb 13 03:04 PM | 1 Like Like |Link to Comment